STAT+: Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Merck and Moderna announced Wednesday that a personalized mRNA cancer vaccine slowed melanoma recurrence and metastasis in a late-stage clinical trial.
- Intismeran, the personalized "neoantigen" vaccine, was combined with Merck's Keytruda as adjuvant therapy for patients whose melanoma had been surgically removed.
- Neoantigen cancer vaccines reached a milestone with the first randomized Phase 3 trial designed to definitively prove their benefit.
- The drugmakers did not immediately release detailed data from the trial, leaving efficacy figures and statistical strength unconfirmed.
- The mRNA platform, if results hold up, gains further validation as a vehicle for therapeutics beyond infectious-disease vaccines, as the source notes.
Why it matters: Melanoma patients facing recurrence after surgery stand to gain a new adjuvant option if results replicate in full data, and the win establishes mRNA as a credible oncology platform beyond infectious-disease vaccines. Neither side has disclosed efficacy figures or a regulatory timeline yet, so the announcement is directional rather than confirmatory.
Ask SkimNews
